Simeon W. Ocran

TL;DR: This report is the first to demonstrate the safety of a recombinant DEN virus tetravalent vaccine in a formal neurovirulence test, as well as its protective efficacy in a monkey challenge model.

TL;DR: This is the first recombinant tetravalent dengue vaccine successfully evaluated in nonhuman primates and no statistically significant difference in levels of neutralizing antibodies was observed between YF virus-immune and nonimmune monkeys which received the tetraValent YF/DEN1-4 vaccine or between tetraavalent Yf/DEN 1-4- immune and non immune monkeys which receive the YF-VAX.

TL;DR: Clustering of beneficial mutations that accumulated after multiple virus passages suggests that the N-terminal part of the prM protein, a specific site in the middle of the E protein, and the NS4B protein may be essential for nucleocapsid-envelope interaction during flavivirus assembly.

TL;DR: A total of 12 nt heterogeneities were detected indicating that the ARILVAX live attenuated yellow fever vaccine is a heterogeneous population and other YF 17D vaccines are undoubtedly also heterogeneous and need to be re-examined using the consensus approach.

TL;DR: Two highly attenuated yellow fever virus chimeras that contain the premembrane-envelope (prM-E) protein genes from the virulent MSI-7 or the naturally attenuated CorAn9124 SLE strains were constructed and were shown to specifically distinguish between confirmed human SLE and WN cases in a virus neutralization test using patient sera.